摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

戈米辛J | 66280-25-9

中文名称
戈米辛J
中文别名
——
英文名称
Gomisin J
英文别名
3,4,15,16-tetramethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaene-5,14-diol
戈米辛J化学式
CAS
66280-25-9
化学式
C22H28O6
mdl
——
分子量
388.461
InChiKey
PICOUNAPKDEPCA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    148-149℃
  • 沸点:
    587.5±50.0 °C(Predicted)
  • 密度:
    1.161
  • 溶解度:
    溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    28
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    77.4
  • 氢给体数:
    2
  • 氢受体数:
    6

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

制备方法与用途

生物活性

Gomisin J 是一种在五味子 (Schisandra chinensis) 中发现的小分子量木脂素,具有血管舒张活性。它通过激活 AMPK、LKB1 和 Ca²⁺/钙调蛋白依赖性蛋白激酶 II 以及抑制 HepG2 细胞中的胎球蛋白-A (fetuin-A),调节脂肪生成、脂肪分解酶和炎症分子的表达,从而抑制脂质积累。因此,在研究非酒精性脂肪性肝病方面具有潜在益处。

靶点
  • AMPK
  • Ca²⁺
化学性质

Gomisin J 是一种白色粉末,可溶于甲醇、乙醇和 DMSO 等有机溶剂。它来源于南五味子。

用途

戈米辛 J 是一种很有前途的抗卵巢癌药物,并且对 SN-8 的葡萄糖醛酸化表现出强烈的抑制作用。此外,它还具有抗氧化作用。

药理药效

适用于含量测定、鉴定和药理实验等。

  • 抗肿瘤
  • 抑制血管收缩
  • 增加冠脉血流(麻醉犬)
  • 抗肝毒
  • 抗氧化剂
  • 保护心肌

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    碘甲烷戈米辛Jpotassium carbonate 作用下, 以 丙酮 为溶剂, 以4.7 mg的产率得到五味子甲素
    参考文献:
    名称:
    Identification of Key Structural Characteristics of Schisandra chinensis Lignans Involved in P-Glycoprotein Inhibition
    摘要:
    The aim of the present study was to determine the structural requirements for dibenzocyclooctadiene lignans essential for P-glycoprotein inhibition. Altogether 15 structurally related lignans isolated from Schisandra chinensis or prepared by modification of their backbone were investigated, including three pairs of enantiomers. P-Glycoprotein inhibition was quantified using a doxorubicin accumulation assay in human promyelotic leukemia HL60/MDR cells overexpressing P-glycoprotein. A preliminary quantitative structure-activity relationship analysis revealed three main structural features involved in P-glycoprotein inhibition: a 1,2,3-trimethoxy moiety, a 6-acyloxy group, and the absence of a 7-hydroxy group. The most effective inhibitors, (-)-gomisin N (1) and (+)-deoxyschizandrin [(+)-2], were selected for further evaluation of their effects. Both these lignans restored the cytotoxic effect of doxorubicin in HL60/MDR cells and when combined with a subtoxic concentration of this compound increased the proportion of G2/M cells significantly, which is a usual response to treatment with this anticancer drug.
    DOI:
    10.1021/np500521v
点击查看最新优质反应信息

文献信息

  • Identification of Key Structural Characteristics of <i>Schisandra chinensis</i> Lignans Involved in P-Glycoprotein Inhibition
    作者:Jiří Slanina、Gabriela Páchniková、Martina Čarnecká、Ludmila Porubová Koubíková、Lenka Adámková、Otakar Humpa、Karel Šmejkal、Iva Slaninová
    DOI:10.1021/np500521v
    日期:2014.10.24
    The aim of the present study was to determine the structural requirements for dibenzocyclooctadiene lignans essential for P-glycoprotein inhibition. Altogether 15 structurally related lignans isolated from Schisandra chinensis or prepared by modification of their backbone were investigated, including three pairs of enantiomers. P-Glycoprotein inhibition was quantified using a doxorubicin accumulation assay in human promyelotic leukemia HL60/MDR cells overexpressing P-glycoprotein. A preliminary quantitative structure-activity relationship analysis revealed three main structural features involved in P-glycoprotein inhibition: a 1,2,3-trimethoxy moiety, a 6-acyloxy group, and the absence of a 7-hydroxy group. The most effective inhibitors, (-)-gomisin N (1) and (+)-deoxyschizandrin [(+)-2], were selected for further evaluation of their effects. Both these lignans restored the cytotoxic effect of doxorubicin in HL60/MDR cells and when combined with a subtoxic concentration of this compound increased the proportion of G2/M cells significantly, which is a usual response to treatment with this anticancer drug.
查看更多